Literature DB >> 23071239

Randomized controlled trials and comparative effectiveness research.

Olwen M Hahn1, Richard L Schilsky.   

Abstract

Comparative effectiveness research (CER) has been promoted as a way to improve the translation gap between clinical research and everyday clinical practice as well as to deliver more cost-effective health care. CER will account for a significant portion of funding allocated by the US government for health care research. Oncology has a rich history of improving clinical outcomes and advancing research through randomized controlled trials (RCTs). In this article, we review the role of RCTs in achieving the goals of CER, with particular emphasis on the role of publicly funded clinical trials.

Mesh：

Year:  2012        PMID： 23071239     DOI： 10.1200/JCO.2012.42.2352

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


  12 in total

Review 1.  The war on cancer: are we winning?

Authors:  M J Duffy
Journal:  Tumour Biol       Date:  2013-04-09

2.  Combining primary cohort data with external aggregate information without assuming comparability.

Authors:  Ziqi Chen; Jing Ning; Yu Shen; Jing Qin
Journal:  Biometrics       Date:  2020-08-25       Impact factor: 1.701

3.  Big Data in Designing Clinical Trials: Opportunities and Challenges.

Authors:  Charles S Mayo; Martha M Matuszak; Matthew J Schipper; Shruti Jolly; James A Hayman; Randall K Ten Haken
Journal:  Front Oncol       Date:  2017-08-31       Impact factor: 6.244

4.  Protocol for a program of research from the Aging, Community and Health Research Unit: Promoting optimal aging at home for older adults with multimorbidity.

Authors:  Maureen Markle-Reid; Jenny Ploeg; Ruta Valaitis; Wendy Duggleby; Kathryn Fisher; Kimberly Fraser; Rebecca Ganann; Lauren E Griffith; Andrea Gruneir; Carrie McAiney; Allison Williams
Journal:  J Comorb       Date:  2018-07-31

5.  The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).

Authors:  David Pérol; Mathieu Robain; Patrick Arveux; Simone Mathoulin-Pélissier; Emmanuel Chamorey; Bernard Asselain; Delphine Berchery; Sophie Gourgou; Mathias Breton; Stéphanie Delaine-Clisant; Muriel Mons; Véronique Diéras; Matthieu Carton; Anne-Valérie Guizard; Lilian Laborde; Carine Laurent; Agnès Loeb; Marie-Ange Mouret-Reynier; Damien Parent; Geneviève Perrocheau; Loïc Campion; Michel Velten; Christian Cailliot; Monia Ezzalfani; Gaëtane Simon
Journal:  BMJ Open       Date:  2019-02-21       Impact factor: 2.692

6.  Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.

Authors:  Clara Natoli; Patrizia Vici; Isabella Sperduti; Antonino Grassadonia; Giancarlo Bisagni; Nicola Tinari; Andrea Michelotti; Germano Zampa; Stefania Gori; Luca Moscetti; Michele De Tursi; Michele Panebianco; Maria Mauri; Ilaria Ferrarini; Laura Pizzuti; Corrado Ficorella; Riccardo Samaritani; Lucia Mentuccia; Stefano Iacobelli; Teresa Gamucci
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-20       Impact factor: 4.553

7.  Comparison of conventional medicine, TCM treatment, and combination of both conventional medicine and TCM treatment for patients with chronic obstructive pulmonary disease: study protocol of a randomized comparative effectiveness research trial.

Authors:  Jian-Sheng Li; Yang Xie; Su-Yun Li; Xue-Qing Yu
Journal:  Trials       Date:  2014-05-01       Impact factor: 2.279

8.  Pharmacoepidemiology in Japan: medical databases and research achievements.

Authors:  Shiro Tanaka; Kahori Seto; Koji Kawakami
Journal:  J Pharm Health Care Sci       Date:  2015-05-01

9.  Selection of external beam radiotherapy approaches for precise and accurate cancer treatment.

Authors:  Hiroki Shirato; Quynh-Thu Le; Keiji Kobashi; Anussara Prayongrat; Seishin Takao; Shinichi Shimizu; Amato Giaccia; Lei Xing; Kikuo Umegaki
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

10.  Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.

Authors:  Mengmeng Zhang; Ling Li; Shiyong Zhang; Wenlong Zhu; Senguo Yang; Guangsheng Di; Xiaoxia Ma; Haisong Yang
Journal:  Biomed Res Int       Date:  2020-05-02       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.